An application made for this job — a tailored resume and cover letter that speak straight to the posting.
To submit your application, scroll to the bottom of this opportunity and click APPLY.
All documents must be in English or include an official English translation.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.
FDA-CDER-2026-0076
6/12/2026 3:00:00 PM Eastern Time Zone
Applications will be reviewed on a rolling-basis.
The Center for Drug Evaluation and Research (CDER), located at St. Louis, Missouri.
This project is located in the Office of Pharmaceutical Quality Research (OPQR), Office of Pharmaceutical Quality (OPQ). The project is to develop liquid chromatography-mass spectrometry (LC‑MS) methods for the analysis of nitrosamine impurities in drug products and apply the developed and validated methods to screen for these impurities in various drug products.
The mentors for this opportunity are Jingyue (Jan) Yang (jingyue.yang@fda.hhs.gov) and Tim Marzan (TimAndres.Marzan@fda.hhs.gov). If you have questions about the nature of the research, please contact the mentors.
2026. Start date is flexible and will depend on a variety of factors.
The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.
The appointment is full time.
The participant will receive a monthly stipend commensurate with educational level and experience.
This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page of the program website for information about the valid immigration statuses that are acceptable for program participation.
Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits. Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.
If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see FDA Ethics for Nonemployee Scientists.
FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:
The qualified candidate should be currently pursuing or have received a master's or doctoral degree in the one of the relevant fields. Degree must have been received within the past five years, or anticipated to be received by 9/30/2026.
Ashley